Singapore markets closed

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1143-0.0071 (-5.85%)
At close: 04:00PM EDT
0.1159 +0.00 (+1.40%)
After hours: 07:57PM EDT
Full screen
Loading interactive chart…
  • Zacks

    Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA

    Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.

  • PR Newswire

    Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

    Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and res

  • PR Newswire

    Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

    Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.